Anthrax Vaccine Work Group

David S. Stephens, MD, FIDSA
ACIP Anthrax Vaccine Work Group

Advisory Committee for Immunization Practices
February 27, 2019
ACIP Anthrax Work Group Members

ACIP Members: David Stephens, Chair; Robert L. Atmar; Sharon Frey

Ex Officio Members: Judy Hewitt (NIH); Amanda Zarrabian (BARDA); Alexandra Worobec (FDA); Eric Deussing (DOD); Kim Taylor (NIH); Chia-Wei Tsai (BARDA); Julianne Clifford (FDA)

Liaison Representatives: Richard Beigi (ACOG); Kathleen Neuzil (IDSA); James Campbell (AAP); Matthew Zahn (NACCHO)

Invited Consultants: Wendy Keitel; Arthur Friedlander; Phillip Pittman; Andy Pavia; Stacy Hall

CDC: William Bower, Lead
Anthrax Vaccine Work Group Activities

- Reconvened in March 2017
- Purpose
  - The US government stockpiles medical countermeasures, including anthrax vaccine and CDC provides guidance for vaccine use and other aspects of preparedness **should there be a wide-area release of Bacillus anthracis spores**
  - The work group considered the body of evidence since last review in 2010 for policy changes to optimize the use of anthrax vaccine for use prior to and following a wide-area release of Bacillus anthracis spores
Today’s Session

1. Informational session on use of new anthrax vaccine, AV7909, for post-exposure prophylaxis (PEP)

2. Policy vote on a change to the pre-exposure prophylaxis (PrEP) booster dose interval for persons who are not at current high risk of exposure to anthrax
ACIP Anthrax Work Group Status

- ACIP Anthrax Work Group will stand down after the MMWR policy updated is published

- We anticipate activating the work group again in 2021-22 to review:
  - AV709 phase 2 and 3 that are currently in progress or planned
  - Data on booster dose intervals of >3 years for PrEP